• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by HilleVax Inc. (Amendment)

    5/31/24 2:00:58 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $HLVX alert in real time by email
    SC 13D/A 1 d798804dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13D

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 4)*

     

     

    HilleVax, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    43157M 102

    (CUSIP Number)

    Steve R. Bailey

    601 Union Street, Suite 3200

    Seattle, WA 98101

    Telephone: (206) 621-7200

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    May 29, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 43157M 102

     

     1.    

     Name of Reporting Persons.

     

     Frazier Life Sciences Public Fund, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (See Instructions)

     

     WC

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

        7.     

     Sole Voting Power

     

     0 shares

        8.   

     Shared Voting Power

     

     1,946,330 shares (1)

        9.   

     Sole Dispositive Power

     

     0 shares

       10.   

     Shared Dispositive Power

     

     1,946,330 shares (1)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,946,330 shares (1)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     3.9% (2)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Consists of 1,946,330 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on 49,720,943 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 9, 2024.

     

    Page 2


    CUSIP No. 43157M 102

     

     1.    

     Name of Reporting Persons.

     

     FHMLSP, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

        7.     

     Sole Voting Power

     

     0 shares

        8.   

     Shared Voting Power

     

     1,946,330 shares (1)

        9.   

     Sole Dispositive Power

     

     0 shares

       10.   

     Shared Dispositive Power

     

     1,946,330 shares (1)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,946,330 shares (1)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     3.9% (2)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Consists of 1,946,330 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on 49,720,943 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 9, 2024.

     

    Page 3


    CUSIP No. 43157M 102

     

     1.    

     Name of Reporting Persons.

     

     FHMLSP, L.L.C.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

        7.     

     Sole Voting Power

     

     0 shares

        8.   

     Shared Voting Power

     

     1,946,330 shares (1)

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     1,946,330 shares (1)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,946,330 shares (1)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     3.9% (2)

    14.  

     Type of Reporting Person (See Instructions)

     

     OO

     

    (1)

    Consists of 1,946,330 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on 49,720,943 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 9, 2024.

     

    Page 4


    CUSIP No. 43157M 102

     

     1.    

     Name of Reporting Persons.

     

     Frazier Life Sciences Public Overage Fund, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (See Instructions)

     

     WC

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

        7.     

     Sole Voting Power

     

     0 shares

        8.   

     Shared Voting Power

     

     60,635 shares (1)

        9.   

     Sole Dispositive Power

     

     0 shares

       10.   

     Shared Dispositive Power

     

     60,635 shares (1)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     60,635 shares (1)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     0.1% (2)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Consists of 60,635 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

    (2)

    Based on 49,720,943 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 9, 2024.

     

    Page 5


    CUSIP No. 43157M 102

     

     1.    

     Name of Reporting Persons.

     

     FHMLSP Overage, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

        7.     

     Sole Voting Power

     

     0 shares

        8.   

     Shared Voting Power

     

     60,635 shares (1)

        9.   

     Sole Dispositive Power

     

     0 shares

       10.   

     Shared Dispositive Power

     

     60,635 shares (1)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     60,635 shares (1)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     0.1% (2)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Consists of 60,635 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

    (2)

    Based on 49,720,943 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 9, 2024.

     

    Page 6


    CUSIP No. 43157M 102

     

     1.    

     Name of Reporting Persons.

     

     FHMLSP Overage, L.L.C.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

        7.     

     Sole Voting Power

     

     0 shares

        8.   

     Shared Voting Power

     

     60,635 shares (1)

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     60,635 shares (1)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     60,635 shares (1)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     0.1% (2)

    14.  

     Type of Reporting Person (See Instructions)

     

     OO

     

    (1)

    Consists of 60,635 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

    (2)

    Based on 49,720,943 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 9, 2024.

     

    Page 7


    CUSIP No. 43157M 102

     

     1.    

     Name of Reporting Persons.

     

     Frazier Life Sciences X, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (See Instructions)

     

     WC

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

        7.     

     Sole Voting Power

     

     0 shares

        8.   

     Shared Voting Power

     

     8,535,337 shares (1)

        9.   

     Sole Dispositive Power

     

     0 shares

       10.   

     Shared Dispositive Power

     

     8,535,337 shares (1)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     8,535,337 shares (1)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     17.2% (2)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Consists of 8,535,337 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

    (2)

    Based on 49,720,943 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 9, 2024.

     

    Page 8


    CUSIP No. 43157M 102

     

     1.    

     Name of Reporting Persons.

     

     FHMLS X, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

        7.     

     Sole Voting Power

     

     0 shares

        8.   

     Shared Voting Power

     

     8,535,337 shares (1)

        9.   

     Sole Dispositive Power

     

     0 shares

       10.   

     Shared Dispositive Power

     

     8,535,337 shares (1)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     8,535,337 shares (1)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     17.2% (2)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Consists of 8,535,337 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

    (2)

    Based on 49,720,943 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 9, 2024.

     

    Page 9


    CUSIP No. 43157M 102

     

     1.    

     Name of Reporting Persons.

     

     FHMLS X, L.L.C.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

        7.     

     Sole Voting Power

     

     0 shares

        8.   

     Shared Voting Power

     

     8,535,337 shares (1)

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     8,535,337 shares (1)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     8,535,337 shares (1)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     17.2% (2)

    14.  

     Type of Reporting Person (See Instructions)

     

     OO

     

    (1)

    Consists of 8,535,337 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

    (2)

    Based on 49,720,943 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 9, 2024.

     

    Page 10


    CUSIP No. 43157M 102

     

     1.    

     Name of Reporting Persons.

     

     Frazier Life Sciences XI, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (See Instructions)

     

     WC

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

        7.     

     Sole Voting Power

     

     0 shares

        8.   

     Shared Voting Power

     

     49,760 shares (1)

        9.   

     Sole Dispositive Power

     

     0 shares

       10.   

     Shared Dispositive Power

     

     49,760 shares (1)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     49,760 shares (1)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     0.1% (2)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Consists of 49,760 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

    (2)

    Based on 49,720,943 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 9, 2024.

     

    Page 11


    CUSIP No. 43157M 102

     

     1.    

     Name of Reporting Persons.

     

     FHMLS XI, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

        7.     

     Sole Voting Power

     

     0 shares

        8.   

     Shared Voting Power

     

     49,760 shares (1)

        9.   

     Sole Dispositive Power

     

     0 shares

       10.   

     Shared Dispositive Power

     

     49,760 shares (1)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     49,760 shares (1)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     0.1% (2)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Consists of 49,760 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

    (2)

    Based on 49,720,943 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 9, 2024.

     

    Page 12


    CUSIP No. 43157M 102

     

     1.    

     Name of Reporting Persons.

     

     FHMLS XI, L.L.C.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

        7.     

     Sole Voting Power

     

     0 shares

        8.   

     Shared Voting Power

     

     49,760 shares (1)

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     49,760 shares (1)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     49,760 shares (1)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     0.1% (2)

    14.  

     Type of Reporting Person (See Instructions)

     

     OO

     

    (1)

    Consists of 49,760 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

    (2)

    Based on 49,720,943 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 9, 2024.

     

    Page 13


    CUSIP No. 43157M 102

     

     1.    

     Name of Reporting Persons.

     

     James N. Topper

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States Citizen

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

        7.     

     Sole Voting Power

     

     0 shares

        8.   

     Shared Voting Power

     

     10,592,062 shares (1)

        9.   

     Sole Dispositive Power

     

     0 shares

       10.   

     Shared Dispositive Power

     

     10,592,062 shares (1)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     10,592,062 shares (1)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     21.3% (2)

    14.  

     Type of Reporting Person (See Instructions)

     

     IN

     

    (1)

    Consists of (i) 1,946,330 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 60,635 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iii) 8,535,337 shares of Common Stock held directly by Frazier Life Sciences X, L.P., and (iv) 49,760 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

    (2)

    Based on 49,720,943 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 9, 2024.

     

    Page 14


    CUSIP No. 43157M 102

     

     1.    

     Name of Reporting Persons.

     

     Patrick J. Heron

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States Citizen

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

        7.     

     Sole Voting Power

     

     47,500 shares (1)

        8.   

     Shared Voting Power

     

     10,592,062 shares (2)

        9.   

     Sole Dispositive Power

     

     47,500 shares (1)

       10.   

     Shared Dispositive Power

     

     10,592,062 shares (2)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     10,639,562 shares (1) (2)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     21.4% (3)

    14.  

     Type of Reporting Person (See Instructions)

     

     IN

     

    (1)

    Consists of 47,500 shares of Common Stock that are issuable upon the exercise of options held directly by Mr. Heron that are exercisable within 60 days of May 29, 2024.

    (2)

    Consists of (i) 1,946,330 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 60,635 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iii) 8,535,337 shares of Common Stock held directly by Frazier Life Sciences X, L.P., and (iv) 49,760 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

    (3)

    Based on (i) 49,720,943 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 9, 2024, and (ii) 47,500 shares of Common Stock that are issuable upon the exercise of options held directly by Mr. Heron that are exercisable within 60 days of May 29, 2024.

     

    Page 15


    CUSIP No. 43157M 102

     

     1.    

     Name of Reporting Persons.

     

     Albert Cha

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States Citizen

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

        7.     

     Sole Voting Power

     

     0 shares

        8.   

     Shared Voting Power

     

     2,006,965 shares (1)

        9.   

     Sole Dispositive Power

     

     0 shares

       10.   

     Shared Dispositive Power

     

     2,006,965 shares (1)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     2,006,965 shares (1)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     4.0% (2)

    14.  

     Type of Reporting Person (See Instructions)

     

     IN

     

    (1)

    Consists of (i) 1,946,330 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., and (ii) 60,635 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

    (2)

    Based on 49,720,943 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 9, 2024.

     

    Page 16


    CUSIP No. 43157M 102

     

     1.    

     Name of Reporting Persons.

     

     James Brush

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States Citizen

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

        7.     

     Sole Voting Power

     

     0 shares

        8.   

     Shared Voting Power

     

     2,006,965 shares (1)

        9.   

     Sole Dispositive Power

     

     0 shares

       10.   

     Shared Dispositive Power

     

     2,006,965 shares (1)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     2,006,965 shares (1)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     4.0% (2)

    14.  

     Type of Reporting Person (See Instructions)

     

     IN

     

    (1)

    Consists of (i) 1,946,330 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., and (ii) 60,635 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

    (2)

    Based on 49,720,943 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 9, 2024.

     

    Page 17


    CUSIP No. 43157M 102

     

     1.    

     Name of Reporting Persons.

     

     Daniel Estes

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States Citizen

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

        7.     

     Sole Voting Power

     

     0 shares

        8.   

     Shared Voting Power

     

     49,760 shares (1)

        9.   

     Sole Dispositive Power

     

     0 shares

       10.   

     Shared Dispositive Power

     

     49,760 shares (1)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     49,760 shares (1)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     0.1% (2)

    14.  

     Type of Reporting Person (See Instructions)

     

     IN

     

    (1)

    Consists of 49,760 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

    (2)

    Based on 49,720,943 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 9, 2024.

     

    Page 18


    CUSIP No. 43157M 102

     

    Item 1.

    Security and Issuer.

    This Amendment No. 4 (“Amendment No. 4”) to Schedule 13D amends the statement on Schedule 13D filed on May 6, 2022 (the “Original Schedule 13D”), as amended on September 8, 2022, May 5, 2023 and September 27, 2023 (the “Prior Amendments”, and together with the Original Schedule 13D and this Amendment No. 4, the “Schedule 13D”) with respect to the Common Stock of HilleVax, Inc. (the “Issuer”), having its principal executive office at 321 Harrison Avenue, Boston, MA 02118. Except as otherwise specified in Amendment No. 4, all items in the Original Schedule 13D, as amended by the Prior Amendments, are unchanged. All capitalized terms used in this Amendment No. 4 and not otherwise defined herein have the meanings ascribed to such terms in the Original Schedule 13D, as amended by the Prior Amendments.

     

    Item 2.

    Identity and Background

     

    (a)

    Name:

    The entities and persons filing this statement (collectively, the “Reporting Persons”) are:

    Frazier Life Sciences Public Fund, L.P. (“FLSPF”)

    FHMLSP, L.P.

    FHMLSP, L.L.C.

    Frazier Life Sciences Public Overage Fund, L.P. (“FLSPOF”)

    FHMLSP Overage, L.P.

    FHMLSP Overage, L.L.C.

    Frazier Life Sciences XI, L.P. (“FLS XI”)

    FHMLS XI, L.P.

    FHMLS XI, L.L.C.

    Frazier Life Sciences X, L.P. (“FLS X”)

    FHMLS X, L.P.

    FHMLS X, L.L.C.

    James N. Topper (“Topper”)

    Patrick J. Heron (“Heron”)

    Albert Cha (“Cha”)

    James Brush (“Brush”)

    Daniel Estes (“Estes” and together with Topper, Heron, Cha and Brush, the “Members”)

     

    (b)

    Residence or Business Address:

    The address of the principal place of business for each of the Reporting Persons is:

    c/o Frazier Life Sciences Management, L.P.

    1001 Page Mill Rd, Building 4, Suite B

    Palo Alto, CA 94304

     

    (c)

    Present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted:

    FLSPF, FLSPOF, FLS XI and FLS X are venture capital funds concentrating in life sciences and related fields. The sole business of FHMLSP, L.P. is to serve as general partner of FLSPF. The sole business of FHMLSP, L.L.C. is to serve as general partner of FHMLSP, L.P. The sole business of FHMLSP Overage, L.P. is to serve as general partner of FLSPOF. The sole business of FHMLSP Overage, L.L.C. is to serve as general partner of FHMLSP Overage, L.P. The sole business of FHMLS XI, L.P. is to serve as general partner of FLS XI. The sole business of FHMLS XI, L.L.C. is to serve as general partner of FHMLS XI, L.P. The sole business of FHMLS X, L.P. is to serve as general partner of FLSPF. The sole business of FHMLS X, L.L.C. is to serve as general partner of FHMLS X, L.P. The principal business of the Members is to manage FLSPF, FHMLSP, L.P., FHMLSP, L.L.C., FLSPOF, FHMLSP Overage, L.P., FHMLSP Overage, L.L.C., FLS XI, FHMLS XI, L.P., FHMLS XI, L.L.C., FLS X, FHMLS X, L.P., FHMLS X, L.L.C. and a number of affiliated partnerships with similar businesses.

     

    (d)

    Whether or not, during the last five years, such person has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) and, if so, give the dates, nature of conviction, name and location of court, and penalty imposed, or other disposition of the case:

    During the last five years, none of the Reporting Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    Page 19


    (e)

    Whether or not, during the last five years, such person was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws; and, if so, identify and describe such proceedings and summarize the terms of such judgment, decree or final order:

    During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)

    Citizenship:

     

    Entities:    FLSPF    -    Delaware, U.S.A.
       FHMLSP, L.P.    -    Delaware, U.S.A.
       FHMLSP, L.L.C.    -    Delaware, U.S.A.
       FLSPOF    -    Delaware, U.S.A.
       FHMLSP Overage, L.P.    -    Delaware, U.S.A.
       FHMLSP, L.L.C.    -    Delaware, U.S.A.
       FLS XI    -    Delaware, U.S.A.
       FHMLS XI, L.P.    -    Delaware, U.S.A.
       FHMLS XI, L.L.C.    -    Delaware, U.S.A.
       FLS X    -    Delaware, U.S.A.
       FHMLS X, L.P.    -    Delaware, U.S.A.
       FHMLS X, L.L.C.    -    Delaware, U.S.A.
    Individuals:    Topper    -    United States Citizen
       Heron    -    United States Citizen
       Cha    -    United States Citizen
       Brush    -    United States Citizen
       Estes    -    United States Citizen

     

    Item 3.

    Source and Amount of Funds or Other Consideration

    Prior to the Issuer’s initial public offering (the “IPO”), and after accounting for the 1-1.681 forward stock split that the Issuer had effected on April 22, 2022, FLS X purchased from the Issuer in a series of private transactions, (i) 4,034,397 shares of the Issuer’s Common Stock for an aggregate purchase price of approximately $2,543, and (ii) convertible promissory notes in the aggregate principal amount of $35,772,111 (the “Notes”). Immediately prior to closing of the IPO, the Notes, including the interest that had accrued thereunder, automatically converted into 2,736,234 shares of Common Stock of the Issuer at a conversion price of $13.60 per share, resulting in FLS X holding a total of 6,770,631 shares of Common Stock at such time. In connection with the IPO, FLS X purchased 1,764,706 shares of Common Stock of the Issuer at the IPO price of $17.00 per share. FLS X holds 8,535,337 shares of Common Stock of the Issuer as of the date of this filing (the “FLS X Shares”).

    In connection with the IPO, FLSPF purchased 588,235 shares of Common Stock of the Issuer at the IPO price of $17.00 per share and has since acquired an additional 1,358,095 shares of Common Stock for a total approximate aggregate purchase price of $18,749,623. FLSPF holds 1,946,330 shares of Common Stock of the Issuer as of the date of this filing (the “FLSPF Shares”).

    Since May 28, 2024, FLSPOF has acquired 60,635 shares of Common Stock for a total approximate aggregate purchase price of $751,234. FLSPOF holds 60,635 shares of Common Stock of the Issuer as of the date of this filing (the “FLSPOF Shares”).

    Since May 28, 2024, FLS XI has acquired 49,760 shares of Common Stock for a total approximate purchase price of $616,498. FLS XI holds 49,760 shares of Common Stock of the Issuer as of the date of this filing (the “FLS XI Shares”).

    The working capital of FLS X, FLSPF, FLSPOF and FLS XI was the source of the funds for the purchase of the FLS X Shares, the FLSPF Shares, the FLSPOF Shares and the FLS XI Shares. No part of the purchase price of the FLS X Shares, the FLSPF Shares, the FLSPOF Shares and the FLS XI Shares was represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the FLS X Shares, the FLSPF Shares, the FLSPOF Shares or the FLS XI Shares.

     

    Page 20


    Item 4.

    Purpose of Transaction

    FLS X, FLSPF, FLSPOF and FLS XI each acquired the FLS X Shares, the FLSPF Shares, the FLSPOF Shares and the FLS XI Shares, as the case me be, for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, each of FLS X, FLSPF, FLSPOF and FLS XI and the other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in:

     

      (a)

    The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

     

      (b)

    An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

     

      (c)

    A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

     

      (d)

    Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

      (e)

    Any material change in the present capitalization or dividend policy of the Issuer;

     

      (f)

    Any other material change in the Issuer’s business or corporate structure;

     

      (g)

    Changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

     

      (h)

    Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

     

      (i)

    A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or

     

      (j)

    Any action similar to any of those enumerated above.

     

    Item 5.

    Interest in Securities of the Issuer

     

    (a)

    State the aggregate number and percentage of the class of securities identified pursuant to Item 1 (which may be based on the number of securities outstanding as contained in the most recently available filing with the Commission by the issuer unless the filing person has reason to believe such information is not current) beneficially owned (identifying those shares which there is a right to acquire) by each person named in Item 2. The information should also be furnished with respect to persons who, together with any of the persons named in Item 2, comprise a group within the meaning of Section 13(d)(3) of the Act:

    FLS X is the record owner of FLS X Shares. As the sole general partner of FLS X, FHMLS X, L.P. may be deemed to beneficially own the FLS X Shares. As the sole general partner of FHMLS X, L.P., FHMLS X, L.L.C. may be deemed to beneficially own the FLS X Shares. As members of FHMLS X, L.L.C., Heron and Topper may each be deemed to beneficially own the FLS X Shares.

    FLSPF is the record owner of FLSPF Shares. As the sole general partner of FLSPF, FHMLSP, L.P. may be deemed to beneficially own the FLSPF Shares. As the sole general partner of FHMLSP, L.P., FHMLSP, L.L.C. may be deemed to beneficially own the FLSPF Shares. As members of FHMLSP, L.L.C., Heron, Topper, Cha and Brush may each be deemed to beneficially own the FLSPF Shares.

    FLSPOF is the record owner of FLSPOF Shares. As the sole general partner of FLSPOF, FHMLSP Overage, L.P. may be deemed to beneficially own the FLSPOF Shares. As the sole general partner of FHMLSP Overage, L.P., FHMLSP Overage, L.L.C. may be deemed to beneficially own the FLSPOF Shares. As members of FHMLSP Overage, L.L.C., Heron, Topper, Cha and Brush may each be deemed to beneficially own the FLSPOF Shares.

    FLS XI is the record owner of FLS XI Shares. As the sole general partner of FLS XI, FHMLS XI, L.P. may be deemed to beneficially own the FLS XI Shares. As the sole general partner of FHMLS XI, L.P., FHMLS XI, L.L.C. may be deemed to beneficially own the FLS XI Shares. As members of FHMLS XI, L.L.C., Heron, Topper and Estes may each be deemed to beneficially own the FLS XI Shares.

    The percentage of outstanding shares of Common Stock of the Issuer, which may be deemed to be beneficially owned by each Reporting Person other than Heron, is set forth on Line 13 of such Reporting Person’s cover sheet. Such percentage was calculated based on 49,720,943 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q as filed with the SEC on May 9, 2024.

     

    Page 21


    The percentage of outstanding shares of Common Stock of the Issuer, which may be deemed to be beneficially owned by Heron, is set forth on Line 13 of Heron’s cover sheet. Such percentage was calculated based on (i) 49,720,943 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q as filed with the SEC on May 9, 2024, and (ii) 47,500 shares of Common Stock that are issuable upon the exercise of options held directly by Heron that are exercisable within 60 days of May 29, 2024.

     

    (b)

    For each person named in response to paragraph (a), indicate the number of shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition. Provide the applicable information required by Item 2 with respect to each person with whom the power to vote or to direct the vote or to dispose or direct the disposition is shared:

    Regarding the number of shares as to which such person has:

     

      a.

    Sole power to vote or to direct the vote: See line 7 of cover sheets.

     

      b.

    Shared power to vote or to direct the vote: See line 8 of cover sheets.

     

      c.

    Sole power to dispose or to direct the disposition: See line 9 of cover sheets.

     

      d.

    Shared power to dispose or to direct the disposition: See line 10 of cover sheets.

     

      (c)

    Describe any transactions in the class of securities reported on that were effected during the past sixty days or since the most recent filing of Schedule 13D (§240.13d-191), whichever is less, by the persons named in response to paragraph (a):

    Information with respect to transactions in the Securities which were effected within the past sixty days or since the most recent filing on Schedule 13D, whichever is less, by the Reporting Persons is set forth below.

    FLSPF:

     

    Date of

    Transaction

     

    Type of

    Transaction

     

    Quantity

     

    Class of Stock

     

    Price Per Share

    (excluding

    commissions)*

    4/4/2024

      Purchase   100,000   Common Stock   $14.5000

    5/14/2024

      Purchase   111,178   Common Stock   $13.4288

    5/15/2024

      Purchase   114,000   Common Stock   $14.0000

    5/22/2024

      Purchase   100,000   Common Stock   $14.7500

    5/23/2024

      Purchase   33,500   Common Stock   $12.9993

    5/28/2024

      Purchase   171,575   Common Stock   $12.2454

    5/29/2024

      Purchase   34,315   Common Stock   $12.5154

    5/30/2024

      Purchase   35,627   Common Stock   $12.9617

     

      *

    Represents the weighted average price per share of shares purchased in one or more transactions on the same day.

    FHMLSP, L.P:

     

    Date of

    Transaction

     

    Type of

    Transaction

     

    Quantity

     

    Class of Stock

     

    Price Per Share

    (excluding

    commissions)

    N/A

      N/A   N/A   N/A   N/A

    FHMLSP, L.L.C.:

     

    Date of

    Transaction

     

    Type of

    Transaction

     

    Quantity

     

    Class of Stock

     

    Price Per Share

    (excluding

    commissions)

    N/A

      N/A   N/A   N/A   N/A

     

    Page 22


    FLSPOF:

     

    Date of

    Transaction

     

    Type of Transaction

     

    Quantity

     

    Class of Stock

     

    Price Per Share

    (excluding

    commissions)*

    5/28/2024

      Purchase   43,075   Common Stock   $12.2454

    5/29/2024

      Purchase   8,615   Common Stock   $12.5154

    5/30/2024

      Purchase   8,945   Common Stock   $12.9617

     

      *

    Represents the weighted average price per share of shares purchased in one or more transactions on the same day.

    FHMLSP Overage, L.P.:

     

    Date of

    Transaction

     

    Type of

    Transaction

     

    Quantity

     

    Class of Stock

     

    Price Per Share

    (excluding

    commissions)

    N/A

      N/A   N/A   N/A   N/A

    FHMLSP Overage, L.L.C.:

     

    Date of

    Transaction

     

    Type of

    Transaction

     

    Quantity

     

    Class of Stock

     

    Price Per Share

    (excluding

    commissions)

    N/A

      N/A   N/A   N/A   N/A

    FLS X:

     

    Date of

    Transaction

     

    Type of

    Transaction

     

    Quantity

     

    Class of Stock

     

    Price Per Share

    (excluding

    commissions)

    N/A

      N/A   N/A   N/A   N/A

    FHMLS X, L.P.:

     

    Date of

    Transaction

     

    Type of

    Transaction

     

    Quantity

     

    Class of Stock

     

    Price Per Share

    (excluding

    commissions)

    N/A

      N/A   N/A   N/A   N/A

    FHMLS X, L.L.C.:

     

    Date of

    Transaction

     

    Type of

    Transaction

     

    Quantity

     

    Class of Stock

     

    Price Per Share

    (excluding

    commissions)

    N/A

      N/A   N/A   N/A   N/A

    FLS XI:

     

    Date of

    Transaction

     

    Type of Transaction

     

    Quantity

     

    Class of Stock

     

    Price Per Share

    (excluding

    commissions)*

    5/28/2024

      Purchase   35,350   Common Stock   $12.2454

    5/29/2024

      Purchase   8,615   Common Stock   $12.5154

    5/30/2024

      Purchase   7,340   Common Stock   $12.9617

     

      *

    Represents the weighted average price per share of shares purchased in one or more transactions on the same day.

    FHMLS XI, L.P.:

     

    Date of

    Transaction

     

    Type of

    Transaction

     

    Quantity

     

    Class of Stock

     

    Price Per Share

    (excluding

    commissions)

    N/A

      N/A   N/A   N/A   N/A

     

    Page 23


    FHMLS XI, L.L.C.:

     

    Date of

    Transaction

     

    Type of

    Transaction

     

    Quantity

     

    Class of Stock

     

    Price Per Share

    (excluding

    commissions)

    N/A

      N/A   N/A   N/A   N/A

    Topper:

     

    Date of

    Transaction

     

    Type of

    Transaction

     

    Quantity

     

    Class of Stock

     

    Price Per Share

    (excluding

    commissions)

    N/A

      N/A   N/A   N/A   N/A

    Heron:

     

    Date of

    Transaction

     

    Type of

    Transaction

     

    Quantity

     

    Class of Stock

     

    Price Per Share

    (excluding

    commissions)

    N/A

      N/A   N/A   N/A   N/A

    Cha:

     

    Date of

    Transaction

     

    Type of

    Transaction

     

    Quantity

     

    Class of Stock

     

    Price Per Share

    (excluding

    commissions)

    N/A

      N/A   N/A   N/A   N/A

    Brush:

     

    Date of

    Transaction

     

    Type of

    Transaction

     

    Quantity

     

    Class of Stock

     

    Price Per Share

    (excluding

    commissions)

    N/A

      N/A   N/A   N/A   N/A

    Estes:

     

    Date of

    Transaction

     

    Type of

    Transaction

     

    Quantity

     

    Class of Stock

     

    Price Per Share

    (excluding

    commissions)

    N/A

      N/A   N/A   N/A   N/A

     

    (d)

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of an employee benefit plan, pension fund or endowment fund is not required:

    No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the FLS X Shares, the FLSPF Shares, the FLSPOF Shares or the FLS XI Shares beneficially owned by any of the Reporting Persons.

     

    (e)

    If applicable, state the date on which the reporting person ceased to be the beneficial owner of more than five percent of the class of securities:

    Not applicable.

     

    Page 24


    Item 6.

    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

    Note Purchase Agreement

    Certain of the Reporting Persons and certain other stockholders of the Issuer entered into Note purchase Agreement dated August 31, 2021 (the “Note Purchase Agreement”), with the Issuer. Under the Note Purchase Agreement, holders of registrable securities, including certain of the Reporting Persons, can demand that the Issuer file a registration statement or request that their registrable shares be included on a registration statement that the Issuer is otherwise filing, in either case, registering the resale of their shares of Common Stock. These registration rights are subject to conditions and limitations, including the right, in certain circumstances, of the underwriters of an offering to limit the number of shares included in such registration.

    Other than as described in this Schedule 13D, to the best of the Reporting Persons’ knowledge, there are no other contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 and between such persons and any person with respect to any securities of the Issuer.

     

    Item 7.

    Material to Be Filed as Exhibits

     

    Exhibit A -    Agreement regarding filing of joint Schedule 13D.
    Exhibit B -    Note Purchase Agreement (incorporated by reference to Exhibit 4.3to the Issuer’s Registration Statement on Form S-1 filed with the Commission on April 6, 2022).

     

    Page 25


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: May 31, 2024     FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.
        By: FHMLSP, L.P., its General Partner
        By: FHMLSP, L.L.C., its General Partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: May 31, 2024     FHMLSP, L.P.
        By:   FHMLSP, L.L.C., its General Partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: May 31, 2024     FHMLSP, L.L.C.
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: May 31, 2024     FRAZIER LIFE SCIENCES X, L.P.
        By:   FHMLS X, L.P., its General Partner
        By:   FHMLS X, L.L.C., its General Partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: May 31, 2024     FHMLS X, L.P.
        By:   FHMLS X, L.L.C., its General Partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: May 31, 2024     FHMLS X, L.L.C.
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer

     

    Date: May 31, 2024     FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P.
        By: FHMLSP Overage, L.P., its General Partner
        By: FHMLSP Overage, L.L.C., its General Partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: May 31, 2024     FHMLSP OVERAGE, L.P.
        By FHMLSP Overage, L.L.C., its General Partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer

     

    Page 26


    Date: May 31, 2024     FHMLSP OVERAGE, L.L.C.
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: May 31, 2024     FRAZIER LIFE SCIENCES XI, L.P.
        By FHMLS XI, L.P., its general partner
        By FHMLS XI, L.L.C., its general partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: May 31, 2024     FHMLS XI, L.P.
        By FHMLS XI, L.L.C., its general partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: May 31, 2024     FHMLS XI, L.L.C.
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer

     

    Date: May 31, 2024     By:  

    *

          James N. Topper
    Date: May 31, 2024     By:  

    *

          Patrick J. Heron
    Date: May 31, 2024     By:  

    **

          Albert Cha
    Date: May 31, 2024     By:  

    **

          James Brush
    Date: May 31, 2024     By:  

    ***

          Daniel Estes
    Date: May 31, 2024     By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, as Attorney-in-Fact

     

    *

    This Schedule 13D was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on February 24, 2017.

    **

    This Schedule 13D was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

    ***

    This Schedule 13D was executed by Steve R. Bailey on behalf of the individual listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022.

     

    Page 27

    Get the next $HLVX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HLVX

    DatePrice TargetRatingAnalyst
    7/9/2024$28.00 → $2.00Outperform → Market Perform
    Leerink Partners
    7/9/2024$34.00 → $3.00Buy → Hold
    Stifel
    7/9/2024$28.00 → $2.00Buy → Neutral
    H.C. Wainwright
    7/8/2024Buy → Neutral
    Guggenheim
    7/8/2024$24.00 → $5.00Overweight → Neutral
    JP Morgan
    12/13/2023$28.00Buy
    H.C. Wainwright
    More analyst ratings

    $HLVX
    SEC Filings

    See more
    • SEC Form 10-Q filed by HilleVax Inc.

      10-Q - HilleVax, Inc. (0001888012) (Filer)

      5/8/25 7:10:20 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HilleVax, Inc. (0001888012) (Filer)

      5/8/25 7:05:08 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13D filed by HilleVax Inc.

      SCHEDULE 13D - HilleVax, Inc. (0001888012) (Subject)

      5/2/25 4:15:10 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

      SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

      11/14/24 9:36:33 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

      SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

      11/14/24 9:00:08 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by HilleVax Inc.

      SC 13G - HilleVax, Inc. (0001888012) (Subject)

      7/22/24 9:02:05 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Gerberding Julie L.

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/30/25 7:00:12 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Chu Shelley

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/30/25 7:00:15 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Hilleman Jeryl L

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/30/25 7:00:11 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Financials

    Live finance-specific insights

    See more

    $HLVX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series

      BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the J.P Morgan Biotech – 2022 Conference Call Series. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion. Fireside chat details:Date:  Tuesday, September 6, 2022Time:  1:00 – 2:00 p.m. Eastern Daylight Time (EDT)Moderator:  Eric Joseph, Ph.D.HilleVax Participant:  Robert Hershberg, M.D., Ph.D.,

      9/1/22 5:18:14 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

      $159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates inadults as well as business development related activities and other strategic alternatives BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2025. First Quarter Financial Results As of March 31, 2025 and December 31, 2024, the company had cash, cash equivalents and marketable securities totaling $159.5 million and

      5/8/25 7:00:30 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Frazier Life Sciences Appoints Aditya Kohli to Partner

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ:HLVX, IPO in 2022)), Phathom Pharmaceuticals (NASDAQ:PHAT, IPO in 2019)), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to se

      4/17/25 8:00:00 AM ET
      $HLVX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress

      $171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2024. Full Year 2024 Financial Results As of December 31, 2024 and December 31, 2023, the company had cash, cash equivalents and marketable securities totaling $171.4 mi

      3/28/25 5:00:00 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HilleVax downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded HilleVax from Outperform to Market Perform and set a new price target of $2.00 from $28.00 previously

      7/9/24 9:48:14 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax downgraded by Stifel with a new price target

      Stifel downgraded HilleVax from Buy to Hold and set a new price target of $3.00 from $34.00 previously

      7/9/24 7:46:22 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded HilleVax from Buy to Neutral and set a new price target of $2.00 from $28.00 previously

      7/9/24 7:46:01 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Leadership Updates

    Live Leadership Updates

    See more
    • Frazier Life Sciences Appoints Aditya Kohli to Partner

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ:HLVX, IPO in 2022)), Phathom Pharmaceuticals (NASDAQ:PHAT, IPO in 2019)), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to se

      4/17/25 8:00:00 AM ET
      $HLVX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

      Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2024, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. "We are excited to remain on track to r

      5/9/24 4:05:00 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer

      BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean McLoughlin as Chief Operating Officer. As part of a planned transition in connection with Mr. McLoughlin's appointment, Co-founder and current Chief Operating Officer Dr. Aditya Kohli will remain a full-time executive with the company as Chief Business Officer, where he will be responsible for business development and corporate strategy.  Mr. McLoughlin has three decades of commercial and operational experience in vaccines, most recently as the Global Vaccine Commercialization Le

      1/18/24 7:00:00 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Frazier Life Sciences X, L.P. bought $128,325 worth of shares (8,850 units at $14.50) (SEC Form 4)

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/8/24 4:22:13 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mcloughlin Sean bought $21,225 worth of shares (1,250 units at $16.98) (SEC Form 4)

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/1/24 4:08:42 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care